Acute Kidney Injury News and Research

RSS

Acute kidney injury (AKI) involves sudden damage to the kidneys or decrease in renal function that occurs over a few hours or days. The severity of the condition can vary from a minor loss of kidney function to kidney failure.

Drinking soft drinks while exercising in hot weather may increase risk of kidney disease

New research suggests that drinking sugary, caffeinated soft drinks while exercising in hot weather may increase the risk of kidney disease. The study is published ahead of print in the American Journal of Physiology--Regulatory, Integrative and Comparative Physiology.

18 Jan 2019

Acutely injured deceased-donor kidneys are suitable for transplant, study suggests

Organ procurement teams are sometimes leery of accepting kidneys from deceased donors with acute kidney injury, fearing they will harm the recipients. However, a national study chaired by a Johns Hopkins kidney specialist suggests these fears may be unfounded.

7 Dec 2018

Protecting powerhouse of cells could provide better way to treat acute kidney injury

For the first time, scientists have described the body's natural mechanism for temporarily protecting the powerhouses of kidney cells when injury or disease means they aren't getting enough blood or oxygen.

6 Dec 2018

D-serine produced by gut microbiota protects against acute kidney injury, show study

The kidney is an organ not only for excreting body waste by urine but also for maintaining body homeostasis in close cooperation with other organs.

27 Nov 2018

New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

The use of a new class of drugs in the treatment of type 2 diabetes, so called SGLT2 inhibitors, are linked to a twofold increased risk for lower-limb amputation as well as diabetic ketoacidosis, a serious diabetes complication.

14 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

High-impact clinical trial results could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2018 October 23-October 28 at the San Diego Convention Center.

26 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Research reveals new ways to better protect the kidneys from essential imaging tests

Every year millions of people undergo medical tests and procedures, such as coronary angiography, which use intravascular contrast dyes.

12 Oct 2018

Dartmouth researchers receive grant to study acute kidney injury

Over two million people in the United States undergo cardiac catheterization each year. While the procedure is used effectively for both diagnostic and interventional purposes, it is not without risk: Acute kidney injury (AKI) occurs in up to 14 percent of all patients following a cardiac catheterization and up to 50 percent in patients with pre-existing kidney disease.

11 Oct 2018

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.

24 Sep 2018

Sesen Bio to present its three-month Phase 3 VISTA Trial data at Global Congress

Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.

20 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Study finds main reasons why people die after noncardiac surgery

The main reasons why people die after noncardiac surgery are revealed today in a study of more than 40,000 patients from six continents presented in a late breaking science session at ESC Congress 2018.

27 Aug 2018

Federal grant extends and expands research into acute kidney failure

The National Institute of Diabetes and Digestive and Kidney Diseases has renewed a grant shared by the University of Alabama at Birmingham School of Medicine and the University of California at San Diego School of Medicine that will extend and expand research into acute kidney failure, or acute kidney injury, which affects about 1.2 million hospitalized patients per year and kills 70 to 80 percent of patients in intensive care units who develop the disease.

22 Aug 2018

Researchers receive multi-million-dollar grant to expand kidney research

Researchers at University of California San Diego School of Medicine and the University of Alabama at Birmingham School of Medicine have received renewed grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases to expand research into the areas of acute kidney failure and acute kidney injuries.

21 Aug 2018

A form of vitamin B3 shows potential to prevent acute kidney injury

Acute kidney injury, an often fatal condition without a specific treatment, affects up to 10 percent of all hospitalized adults in the United States and 30-40 percent in low-income countries.

21 Aug 2018

Acute Kidney Injury News and Research

Further Reading

Drinking soft drinks while exercising in hot weather may increase risk of kidney disease

Acutely injured deceased-donor kidneys are suitable for transplant, study suggests

Protecting powerhouse of cells could provide better way to treat acute kidney injury

D-serine produced by gut microbiota protects against acute kidney injury, show study

New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

High-impact clinical trial results could affect kidney-related medical care

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Research reveals new ways to better protect the kidneys from essential imaging tests

Dartmouth researchers receive grant to study acute kidney injury

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

Sesen Bio to present its three-month Phase 3 VISTA Trial data at Global Congress

FDA approves new treatment for people with hairy cell leukemia

Study finds main reasons why people die after noncardiac surgery

Federal grant extends and expands research into acute kidney failure

Researchers receive multi-million-dollar grant to expand kidney research

A form of vitamin B3 shows potential to prevent acute kidney injury

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News